Mark J. Mitton-Fry

发表

New analyses of MIC90 data to aid antibacterial drug discovery

Max Kuhn, Matthew Frank Brown, Rishi R. Gupta, 2011 .

Novel bacterial topoisomerase inhibitors derived from isomannide.

Mark J. Mitton-Fry, J. Gallucci, A. Okumu, 2020, European journal of medicinal chemistry.

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Mark J. Mitton-Fry, J. D. Clark, M. Hegen, 2018, Journal of medicinal chemistry.

Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs

Mark J. Mitton-Fry, J. Yalowich, M. Mitton-Fry, 2023, Antimicrobial agents and chemotherapy.

Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors Exhibit Bactericidal Activity against Planktonic and Biofilm Staphylococcus aureus In Vitro

Mark J. Mitton-Fry, D. Wozniak, Anna Chen, 2022, Microbiology spectrum.

1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition.

Mark J. Mitton-Fry, S. Lindert, L. Koeth, 2019, ACS infectious diseases.

Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide

Mark J. Mitton-Fry, R. Wallis, D. Paige, 2012, PloS one.

Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.

Mark J. Mitton-Fry, S. Lindert, D. Wozniak, 2020, ACS medicinal chemistry letters.

Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks

Mark J. Mitton-Fry, N. Osheroff, Jessica A Collins, 2023, International journal of molecular sciences.

Antibacterial activity of novel bacterial topoisomerase inhibitors against key veterinary pathogens.

Mark J. Mitton-Fry, M. Kuhn, J. Watts, 2023, Veterinary microbiology.

1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.

Mark J. Mitton-Fry, N. Osheroff, M. Hazbón, 2022, ACS medicinal chemistry letters.

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.

Mark J. Mitton-Fry, S. Lindert, C. McElroy, 2021, Journal of medicinal chemistry.

Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.

Mark J. Mitton-Fry, A. Okumu, D. Wozniak, 2018, Bioorganic & medicinal chemistry letters.

Novel Bacterial Type II Topoisomerase Inhibitors

Mark J. Mitton-Fry, M. Mitton-Fry, 2017 .

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2017, Bioorganic & medicinal chemistry letters.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2013, Bioorganic & medicinal chemistry letters.

Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.

Mark J. Mitton-Fry, V. Shanmugasundaram, Ye Che, 2012, Bioorganic & medicinal chemistry letters.

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

Mark J. Mitton-Fry, R. Wallis, Vikas Kumar, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

Mark J. Mitton-Fry, G. Friedland, R. Wallis, 2010, The Journal of infectious diseases.